Moreover, global heterozygous deletion of TBK1 modelling the TBK1 loss-of-function mutations found in ALS/FTD in humans, was seen to exert a dual and stage-specific effect in SOD1G93A mice, by initially preponing muscular denervation and clinical onset, but reducing microglial neuroinflammation and decelerating disease progression at later stages [28]. The gene discussed is TBK1; the disease is frontotemporal dementia.